Influences of excipients on in vitro release and in vivo performance of tetanus toxoid loaded polymer particles.
Protein instability during microencapsulation has been one of the major hurdles of biodegradable polymer particles-based vaccine delivery systems. In the present work, effect of serum albumin, sucrose and sodium bicarbonate on surface morphology, entrapment efficiency, in vitro release and in vivo performance tetanus toxoid (TT) loaded PLA particles were investigated. Use of serum albumin as well as high concentration of protein antigen ( approximately 60mg/ml) helped in protecting the immunoreactivity of the antigen during primary emulsification step of particle formulation. Incorporation of sucrose in the internal aqueous phase led to the reduction in encapsulation efficiency of TT from 43.8+/-4.3% to 27.3+/-3.6% in PLA particles and resulted with formation of particles having irregular surface characteristics. Addition of sodium bicarbonate along with sucrose during primary emulsion led to slight improvement in encapsulation efficiency of TT (34.3+/-3.2%) but affected the in vivo performance in terms of serum anti-TT antibody titers from single point immunization. Restoration of osmotic balance by adding equivalent amount of sucrose in external aqueous phase helped in preventing multiple emulsion instability and subsequently improved the encapsulation efficiency of TT to 63.1+/-4.2%. Maximum entrapment efficiency of TT up to 69.2+/-5.1% was achieved when serum albumin, sucrose and sodium bicarbonate were used in internal aqueous phase and sucrose was used in the external aqueous phase. Polymer particles entrapping tetanus toxoid along with optimal stabilizers showed burst release of immunoreactive antigen (>40% in early period) and elicited high and sustained anti-TT antibody titers from single point intramuscular immunization. Anti-TT antibody titers were further enhanced upon immunization of admixture of PLA particles and alum. Choice and use of stabilizers during particle formulation thus need careful considerations not only to protect the immunoreactivity of the antigen, but also to produce stable, uniform particles for optimal in vivo performances.
Katare
Yogesh K
YK
National Institute of Immunology, Aruna Asaf Ali Marg, New Delhi 110067, India.
Panda
Amulya K
AK
D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000534:Alum Compounds / Q000008:administration & dosage; D000818:Animals; D000906:Antibodies / Q000097:blood; D002626:Chemistry, Pharmaceutical; D004337:Drug Carriers; D004339:Drug Compounding; D004355:Drug Stability; D005079:Excipients / Q000737:chemistry*; D005260:Female; D007273:Injections, Intramuscular; D008863:Microspheres; D011091:Polyesters / Q000737:chemistry*; D011489:Protein Denaturation; D051381:Rats; D017208:Rats, Wistar; D012709:Serum Albumin / Q000737:chemistry; D017693:Sodium Bicarbonate / Q000737:chemistry; D012995:Solubility; D013395:Sucrose / Q000737:chemistry; D013499:Surface Properties; D013745:Tetanus Toxoid / Q000008:administration & dosage / Q000737:chemistry* / Q000276:immunology; D013997:Time Factors; D014611:Vaccination / Q000379:methods
D000276:Adjuvants, Immunologic; D000534:Alum Compounds; D000906:Antibodies; D004337:Drug Carriers; D005079:Excipients; D011091:Polyesters; D012709:Serum Albumin; D013745:Tetanus Toxoid; C041524:aluminum sulfate; C033616:poly(lactide); D013395:Sucrose; D017693:Sodium Bicarbonate